Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

Georg Lenz

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

State of the Art and Next Questions: B-Cell Lymphoma

SOHO Highlights: State of the Art and Next Questions

L. Nastoupil

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

SOHO Highlights: State of the Art and Next Questions

G. Nowakowski

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

Juan Pablo Alderuccio

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

New Treatment Strategies in DLBCL

UChicago Medicine

L. Sehn

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

Daniel Addison

CLL/SLL: Outcomes of Pts With Richter's Transformation Without Prior…

Insights from 2023 ASH Annual Meeting

A. Kittai

What's Current in Immunotherapy in DLBCL and FL

Houston Methodist

A. Mehta

DLBCL Pts Ineligible for CAR-T Therapy: Do They Exist and How Do We …

SOHO Brazil 2024

A. Zelenetz